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ABSTRACT
Objectives: Chronic transplant dysfunction after
kidney transplantation is a major reason of kidney graft
loss and is caused by immunological and non-
immunological factors. There is evidence that
mycophenolate mofetil (MMF) may exert a positive
effect on renal damage in addition to
immunosuppression, by its direct antifibrotic
properties. The aim of our study was to retrospectively
investigate the role of MMF doses on progression of
chronic allograft dysfunction and fibrosis and tubular
atrophy (IF/TA).
Setting: Retrospective, cohort study.
Participants: Patients with kidney transplant in a
tertiary care institution. This is a retrospective cohort
study that included 79 patients with kidney and
kidney–pancreas transplantation. Immunosuppression
consisted of anti-interleukin 2 antibody induction,
MMF, a calcineurin inhibitor±steroids.
Primary outcome measures: An association of
average MMF doses over 1 year post-transplant with
progression of interstitial fibrosis (Δci), tubular atrophy
(Δct) and estimated-creatinine clearance (eCrcl) at
1 year post-transplant was evaluated using univariate
and multivariate analyses.
Results: A higher average MMF dose was significantly
independently associated with better eCrcl at 1 year
post-transplant (b=0.21±0.1, p=0.04). In multiple
regression analysis lower Δci (b=−0.2±0.09, p=0.05)
and Δct (b=−0.29±0.1, p=0.02) were independently
associated with a greater average MMF dose. There
was no correlation between average MMF doses and
incidence of acute rejection (p=0.68).
Conclusions: A higher average MMF dose over 1 year
is associated with better renal function and slower
progression of IF/TA, at least partly independent of its
immunosuppressive effects.
INTRODUCTION
Kidney transplantation signiﬁcantly improves
patient survival and quality of life as com-
pared to dialysis. While signiﬁcant
improvements have been made in the treat-
ment of acute rejection and short survival of
transplanted kidney, there has not been any
major improvement in the long-term survival
of transplanted kidney.1 Chronic transplant
dysfunction after kidney transplantation is a
major cause of kidney graft loss and is
evoked by immunological and non-
immunological factors.2 3 Histology changes
that determine chronic transplant dysfunc-
tion are interstitial ﬁbrosis and tubular
atrophy (IF/TA), arteriosclerosis, arteriolar
hyalinosis, glomerulopathy and mesangial
matrix expansion.4 IF/TA is the major patho-
hystology ﬁnding that can be veriﬁed on
graft biopsies after kidney transplantation
and is a predictor of long-term allograft func-
tion.4 Clinical factors that affect progression
of IF/TA are: recipient age, human leucocyte
antigen (HLA) mismatch, episodes of severe
Strengths and limitations of this study
▪ An important novel finding in our study is that
greater average mycophenolate mofetil (MMF)
exposure was strongly negatively correlated with
fibrosis and tubular atrophy (IF/TA) progression
during the first year after kidney transplantation.
▪ Patients on higher average doses of MMF (up to
4 g daily) during 1 year post-transplantation had
significantly lower progression of graft interstitial
fibrosis and tubular atrophy. This is an important
finding because of the predictive value of graft
IF/TA and should translate into better long-term
graft survival.
▪ Our study has several shortcomings, such as its
retrospective aspect and relatively short study
period.
▪ As it was not the aim of the study, we did not
report side effects associated with different
dosages of MMF.
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acute rejection, chronic rejection (especially antibody
mediated), use of calcineurin inhibitors (CNI) and BK
nephropathy. Avoidance of CNI toxicity is considered as
an important step to slow progression of IF/TA.4–7
Mycophenolate mofetil (MMF) may help in lowering
CNI toxicity, by allowing lower CNI exposure.7
MMF reduces the risk of acute allograft rejection,
without nephrotoxic side effects, and is an ideal candidate
for long-term calcineurin drug reduction treatment strat-
egies.7 Retrospective studies of renal recipients who were
treated with MMF comparing azathioprin showed that
MMF-treated patients had signiﬁcantly less chronic allo-
graft dysfunction.8 9 Besides being associated with lower
acute rejection rates as compared to azathioprin,10 11 evi-
dence from animal and human studies suggests that MMF
may also exert direct antiﬁbrotic properties due to its anti-
proliferative action on non-immune cells, including renal
tubular cells and vascular smooth muscle cells.12 13
The aim of our study was to investigate the role of
MMF doses on progression of IF/TA in kidney trans-
plant recipients.
PATIENTS AND METHODS
Patients
This is a retrospective study conducted at Clinical
Hospital ‘Merkur’. This study represents a part of the
post-transplant immune monitoring at the Merkur hos-
pital, approved by the Hospital Ethics Committee.
Patients gave their informed written consent for anon-
ymised transplant data collection for research purposes.
The study included 79 patients with kidney and kidney-
pancreas transplantation performed between 2003 and
2011. Eligible patients had to have protocol kidney
biopsy at the time of implantation and 12 months after
transplantation. Exclusion criteria have been: dual
kidney transplantation, kidney–liver transplantation, use
of antithymocyte immunoglobulin, BK nephropathy and
recurrence of glomerulonephritis after transplantation.
Immunosuppression
Induction immunosupression consisted of an anti-
interleukin 2 (IL2) antibody (daclizumab or basiliximab),
CNI (tacrolimus or cyclosporine), MMF and methylpred-
nisolone. Maintenance immunosuppression consisted of
a CNI (tacrolimus or cyclosporine), MMF±steroids. Target
cyclosporine trough concentrations were 250–350 during
ﬁrst month post-transplant, 200–300 during second to
sixth months and 100–150 µg/L thereafter. Target tacroli-
mus trough levels were 10–12 during ﬁrst month, 8–10
during second to sixth months and 5–8 µg/L thereafter.
Mycophenolic acid target trough concentration was
aimed to be higher than 7.2 µmol/L with tacrolimus and
higher than 5 µmol/L with cyclosporine use.
Daclizumab was administered at day 0 in a dose of
2 mg/kg intravenously before opening of vascular anasto-
mosis and at day 14 in a dose of 2 mg/kg intravenously.
Basiliximab was administered at day 0 in a dose of 20 mg
intravenously before opening of vascular anastomosis and
at day 4 as 20 mg intravenously.
Steroids were dosed as follows: day 0: intraoperatively
500 mg of methylprednisolone, day 1 250 mg, day 2
125 mg, day 3 80 mg and day 4 40 mg. In patients with
early steroid withdrawal steroids were withdrawn at day 5
after transplantation. In patients maintained on steroids,
nadir dose of prednisone was 5 mg/day, achieved by
6 months. The criteria for early elimination of steroids
were low immunological risk of the recipient (absence of,
or low degree of HLA sensitisation, ie, panel reactive anti-
bodies <10%) and good immediate renal function, as
well as absence of an episode of acute rejection within
5 days after the transplantation. Steroids were reintro-
duced in patients who suffered acute rejection episodes.
As prophylaxis for viral (herpes simplex virus, cyto-
megalovirus), fungal (Candida spp.) urinary and
Pneumocystis jiroveci infections, low-dose ﬂuconazole (for
1 year), valganciclovir (universally for 3 months) and sul-
famethoxazol and trimethoprim (for 1 year) were used.
Renal allograft biopsies
Protocol kidney biopsies were performed at implantation
and 1, 3, 6 and 12 months after transplantation. For
cause, biopsies were performed in case of unexplained
deterioration of renal function, or once weekly in
patients with delayed graft function (DGF). All rejection
episodes were histologically conﬁrmed. Histopathological
analysis was performed by either of two pathologists who
were blinded for immunosuppression. Acute rejections
and chronic allograft scores were analysed using Banff 97
classiﬁcation and its updates.14 15 All protocol and indica-
tion biopsies were analysed by light microscopy, by
immunoﬂuorescence for C4d and, if indicated by immu-
nohistochemistry, for BK virus. Biopsies at 1 year post-
transplant were also analysed by electron microscopy for
signs of chronic antibody-mediated rejection (transplant
glomerulopathy, peritubular capillary basement mem-
brane multilayering).16
Clinical outcome parameters
Progression of chronic allograft scores during 1 year
post-transplant was calculated by subtracting implant-
ation chronic scores from chronic allograft scores
12 months post-transplant: interstitial ﬁbrosis (Δci),
tubular atrophy (Δct), glomerulosclerosis (Δcg), mesan-
gial matrix increase (Δmm), vasculopathy (Δcv) and
arteriolar hyalinosis (Δah). Estimated creatinine clear-
ance (eCrcl) at 3, 6 and 12 months post-transplant was
calculated using Cockroft-Gault formula. Acute rejec-
tions with Banff grade IA and IB were treated with three
500 mg methylprednisolone pulses. In case of acute
rejection grade IIA or greater, patients were treated with
antithymocyte globulin. Antibody-mediated rejections
were treated with steroid pulse and plasmapheresis.
The average dose of MMF during 1 year post-
transplant was calculated from MMF doses at months 1,
3, 6 and 12.
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Adverse effects analysed were clinically signiﬁcant leu-
copaenia, deﬁned as white cell count less than 3000/
mL, time to ﬁrst symptomatic infection and number of
symptomatic infection episodes per patient during the
ﬁrst post-transplant year.
Statistical analysis
Numerical data are presented as mean±SD or median
with range in case of not normal distribution. Normality
of distribution was tested with Kolmogorov-Smirnov test.
Correlation between two continuous variables was tested
using Spearman non-parametric correlation. Difference
between two groups in continuous variables was tested
with student t test or with Mann-Whitney test in non-
normally distributed variables. The signiﬁcance of the
progression in chronic scores was analysed using
Wilcoxon Matched Pairs test. Univariate and multiple
linear regression analyses were performed to determine
predictive factors for progression of chronic allograft
scores and kidney function at 12 months after trans-
plantation. All variables that were associated with
respective outcome in bivariate analysis (at p=0.1) were
included in the multivariate analysis. Owing to
co-linearity between ci and ct scores, only one score was
included in each multivariate analysis. Statistical signiﬁ-
cance was considered at p<0.05. All statistical analyses
were performed using Statistica V.10 (StatSoft, Tulsa,
Oklahoma, USA).
RESULTS
Patient and transplant characteristics
Patient characteristics are shown in table 1. Recipients
were a mean of 44.67±12.03-years old at the time of
transplantation, 68% were men and all were Caucasians.
Thirty-three per cent of recipients had DGF after trans-
plantation. Donors were a mean of 43.89±15.55 years old
and 54% were men. The number of living donor trans-
plantations was 24 (30%). The average daily MMF dose
during 1 year post-transplant was 2244±585 mg (1062–
4000; table 2). As expected, there was no correlation of
MMF dose with MMF trough concentration (R=−0.13;
p=0.28). Also, there was no correlation between MMF
dose with tacrolimus concentration (R=−0.04; p=0.79).
Early steroid withdrawal was carried out in 46% of
patients after transplantation. Incidence of subclinical
and clinical acute rejections greater than borderline was
30% in the ﬁrst year. There was no correlation between
average MMF dose and incidence of acute rejection
(p=0.68).
Factors associating with eCrcl
Kidney function increased during ﬁrst year post-
transplant. eCrcl at month 3 was 56.98±15.78 mL/min,
at 6 months 58.94±16.94 mL/min and at 12 months
61.47±16.75 mL/min (p<0.001; 12 months versus
3 months; ﬁgure 1.) eCrcl at 1 year post-transplant was
greater in simultaneous pancreas–kidney transplant reci-
pients (71.38±13.45 vs 57.88±16.47 mL/min; p=0.001)
and in patients who did not have DGF (64.08±15.87 vs
56.15±17.55 mL/min; p=0.05). Donor age (R=−0.46;
p<0.001) and recipient age (R=−0.46; p<0.001) nega-
tively correlated with eCrcl at 1 year post-transplant,
while there was no correlation of renal function with
donor and recipient gender, type of donation (deceased
vs living), HLA MM, average CNI concentration, steroid-
free regimen of immunosuppression or history of acute
Table 2 eCrcl, MMF dose and CNI concentration during first year post-transplant
Month post-transplant 1 3 6 12
eCrcl (mL/min) 56.98±15.79 58.94±16.94 61.47±16.75
MMF dose (mg) 2500 (750–4000)
2427±643.17
2000 (750–4000)
2167.72±733.49
2000 (1000–4000)
2188.29±716.91
2000 (1000–4000)
2193.04±642.95
Tacrolimus concentration (µg/L)
(n=53)
10.79±4.16 9.69±3.00 9.03±5.52 7.83±2.45
Cyclosporin concentration (µg/L)
(n=26)
335.07 (274–413) 231.05 (181–265) 206 (170–257) 131 (125–171)
CNI, calcineurin inhibitors; eCrcl, estimated-creatinine clearance (eCrcl); MMF, mycophenolate mofetil.
Table 1 Baseline characteristics
Recipient characteristics
Age (years) 44.67±12.03
Gender (female/male) 25/54
Primary renal disease (diabetes mellitus,
polycistic kidney disease,
glomerulonephritis, pyelonephritis/
interstitial nephritis, other/unknown)
24/8/19/6/22
Donor characteristics
Donor source (deceased/living) 55/24
Age (years) 43.89±15.55
Gender (female/male) 36/43
Transplantation characteristics
Transplanted organ (KIDNEY/SPKT) 58/21
Initial immunosuppression (anti-IL2, TAC,
MMF/anti-IL2, CyA, MMF)
53/26
Delayed graft function (no/yes) 53/26
Steroid free (yes/no) 36/43
HLA MM 3.33±1.51
HLA, human leucocyte antigen; Il2, interleukin 2; MMF,
mycophenolate mofetil; MM, mismatch; SPKT, simultaneous
pancreas-kidney transplant.
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rejection (table 3). In univariate analysis allograft func-
tion at 12 months post-transplant was also negatively cor-
related with ci (R=−0.34; p=0.002) and ct (R=−0.35;
p=0.002) at 12 months (ﬁgure 2A, B). Although the
MMF dose was positively correlated with renal function
with borderline signiﬁcance in univariate analysis, in
multivariate analysis there was a signiﬁcant positive asso-
ciation between a greater average MMF dose and better
eCrcl at 12 months post-transplant (b=0.21±0.1; p=0.04;
table 4).
Factors affecting IF/TA
The average ci score increased from 0.16±0.44 to 0.94
±0.86 between implantation and month 12 (p<0.001).
Figure 1 Estimated-creatinine clearance during first year
post-transplant.
Table 3 Association of variables with eCrcl on 1 year
Estimated-creatinine clearance (mL/min) p Value
Kidney vs SPKT 57.88±15.47 vs 71.38±13.45 0.001
DGF (yes vs no) 56.15±17.55 vs 64.08±15.87 0.05
Recipient gender (m vs f) 59.83±16.02 vs 65±18.07 0.2
Donor gender (m vs f) 63.87±16.71 vs 58.60±16.58 0.17
Donor source (D vs L) 62.36±17.85 vs 59.43±14.05 0.47
Steroid-free (yes vs no) 63.94±17.73 vs 59.39±15.81 0.23
Acute rejection (yes vs no) 61.64±16.59 vs 61.39±16.97 0.95
R p Value
Recipient age −0.45 <0.001
Donor age −0.46 <0.001
HLA MM 0.07 0.52
Average tacrolimus concentration −0.02 0.9
Average MMF dose 0.18 0.1
ci at 1 year post-transplantation −0.34 0.002
ct at 1 year post-transplantation −0.35 0.002
cv at 1 year post-transplantation −0.20 0.07
DGF, delayed graft function; HLA, human leucocyte antigen; MMF, mycophenolate mofetil; MM, mismatch; SPKT, simultaneous
pancreas-kidney transplant.
Figure 2 Correlation between average mycophenolate
mofetil dose and progression of (A) ci score and (B) ct score.
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Average progression of this and other chronic scores
during 1 year post-transplant is shown in table 5. In uni-
variate analysis Δci (R=−0.37; p=0.001) and Δct (R=−0.38;
p=0.001) signiﬁcantly negatively correlated with average
MMF dose (ﬁgure 3A, B, table 6). There was lower pro-
gression of ci score in patients on steroid-free immuno-
suppression (0.47±0.7 vs 1.09±0.87; p=0.002) and in
those who did not have DGF (0.62±0.74 vs 1.19±0.98;
p=0.02). Acute cellular rejection, recipient and donor
gender, recipient and donor age, HLA MM, deceased vs
living donor, as well as average concentration of tacroli-
mus had no signiﬁcant effect on progression of chronic
allograft scores. A higher average MMF dose was asso-
ciated with lower progression of ci and ct score regard-
less of CNI type (data not shown). Factors that remained
signiﬁcantly associated with progression of ci score in
multivariate analysis were ci score, donor age, average
MMF dose, DGF and steroid-free immunosuppression
(table 7). In multivariate analysis only ct0 score, average
MMF dose and DGF remained independently associated
with a 12-month progression of ct score (table 7);
selected adverse events (AE) are shown in table 8. There
was no difference in AE (leucopaenia and infections)
with respect to average median MMF dose.
DISCUSSION
The most important novel ﬁnding in our study is that
greater average MMF exposure was strongly negatively
correlated with IF/TA progression during ﬁrst year after
kidney transplantation. Patients on higher average doses
of MMF during 1 year post-transplantation had signiﬁ-
cantly lower progression of ci and ct scores. To our
knowledge, this is the ﬁrst study demonstrating that
there is a dose-dependent protective effect of MMF on
graft IF/TA. Lower progression of IF/TA could not be
explained with lower concentration of CNI, because
Table 4 Multiple regression analysis of factors associated
with kidney function
Beta (β) SE β p Value
Tx (kidney) −0.17 0.13 0.19
DGF (no) 0.04 0.1 0.71
Recipient age −0.41 0.1 <0.001
Donor age −0.1 0.14 0.45
ci at 12 months −0.18 0.11 0.09
Average MMF dose 0.21 0.1 0.04
DGF, delayed graft function; MMF,mycophenolate mofetil.
Table 5 One-year progression of chronic allograft scores
Banff score N At transplantation N 12 month p Value
Interstitial fibrosis (ci) 79 0.16±0.44 79 0.94±0.85 <0.001
Tubular atrophy (ct) 79 0.24±0.46 79 1.05±0.77 <0.001
Chronic glomerulopathy (cg) 79 0 79 0
Mesangial matrix (mm) 79 0.01±0.11 79 0.09±0.36 0.09
Fibrointimal thickening (cv) 76 0.37±0.83 78 0.29±0.70 0.47
Arteriolar hyalinosis (ah) 78 0.68±1.04 79 0.79±1.04 0.26
Figure 3 Estimated-creatinine clearance by (A) ci score and
(B) ct score.
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there was no correlation between tacrolimus concentra-
tion with IF/TA. Similarly, there was no correlation
between average MMF dose and tacrolimus (R=−0.04;
p=0.79) or cyclosporine concentration (R=−0.07,
p=0.79). In addition, a higher average MMF dose was
not associated with decreased incidence of biopsy
proven acute rejection, which suggests that antiﬁbrotic
properties of a higher MMF dose was at least partly inde-
pendent of its immunosuppressive effects. Higher MMF
doses had only moderate effect on 1-year renal function,
which is consistent with previous reports showing that
transplanted kidneys undergo pathohystology changes
without signiﬁcant early change in kidney function.4
In the present retrospective study we have conﬁrmed
that IF/TA progression occurs in the ﬁrst year after
kidney transplantation. Several studies have shown that
progression of IF/TA is correlated with a type of
immunosuppression.17 In most transplant centres in the
USA and Europe, immunosuppression consists of
induction with an anti-IL2R antibody or antithymocyte
immunoglobulin and maintenance with a CNI, MMF
and steroids.18 Studies have reported signiﬁcant
improvement in kidney function in patients on MMF
with lower exposition to CNIs, especially tacrolimus.19
Recently, Kamar et al20 reported that maintenance
patients with kidney transplant who converted to a
higher dose of mycophenolate sodium (1440 mg daily)
with lower tacrolimus concentration had borderline
higher eCrcl on month 6 vs those treated with a lower
dose of mycophenolate sodium, with usual tacrolimus
concentration (eCrcl 49.1±11.1 vs 44.7±11.5 mL/min;
p=0.07). Although there was only borderline signiﬁ-
cance, increased mycophenolate dosing with lower tacro-
limus concentration was safe with potential beneﬁt on
kidney function.
Our study also corroborates recently published ﬁnd-
ings of a post hoc joint analysis of the Symphony, FDCC
and OptiCept trials, where a lower tacrolimus level and a
higher MMF dose were associated with signiﬁcantly
better kidney function at 1 year post-transplant.19
Table 6 Correlation of factors associated with progression of ci and ct scores
Δci Δct
Mean±SD p Value Mean±SD p Value
Kidney vs SPKT 0.86±0.91 vs 0.67±0.73 0.51 0.85±0.87 vs 0.86±0.65 0.74
DGF (yes vs no) 1.19±0.98 vs 0.62±0.74 0.02 1.15±0.92 vs 0.69±0.72 0.05
Recipient gender (male vs female) 0.83±0.88 vs 0.76±0.83 0.78 0.91±0.83 vs 0.72±0.79 0.35
Donor gender (male vs female) 0.91±0.95 vs 0.69±0.75 0.43 0.88±0.93 vs 0.81±0.67 0.96
Donor source (D vs L) 0.84±0.88 vs 0.75±0.85 0.73 0.87±0.82 vs 0.79±0.83 0.71
Steroid free (no vs yes) 1.09±0.87 vs 0.47±0.74 0.002 1.07±0.83 vs 0.58±0.73 0.01
Acute rejection (yes vs no) 0.8±0.89 vs 0.83±0.82 0.78 0.93±0.84 vs 0.67±0.76 0.23
R p Value R p Value
Recipient age −0.11 0.33 −0.11 0.32
Donor age 0.17 0.13 0.04 0.73
HLA MM −0.09 0.43 −0.002 0.99
Average tacrolimus concentration −0.009 0.95 0.003 0.98
Average MMF dose −0.37 <0.001 −0.38 <0.001
ci at implantation −0.32 0.003
ct at implantation −0.45 <0.001
DGF, delayed graft function; HLA, human leucocyte antigen; MM, mismatch; SPKT, simultaneous pancreas-kidney transplant.
Table 7 Multivariate general regression analysis for
factors related to progression of ci and ct score
Beta (β) SE β p Value
Δci
ci0 −0.43 0.09 <0.001
DGF (no) −0.22 0.11 <0.05
Average MMF dose −0.20 0.09 <0.05
Donor age 0.32 0.09 <0.05
Steroid free (yes) −0.25 0.11 0.02
Δct
ct0 −0.44 0.09 <0.001
Average MMF dose −0.29 0.1 <0.05
DGF (no) −0.29 0.1 <0.05
Steroid free (yes) −0.09 0.11 0.39
DGF, delayed graft function; MMF, mycophenolate mofetil.
Table 8 Adverse events with respect to 1 year average
median MMF dose
MMF dose
<median
MMF dose
>median p Value
Average number of
infection episodes
per patient
1.16±0.97 1.23±1.22 0.88
Mean time to first
infection (days)
157±138 175±143 0.76
Proportion of patients
with leucopaenia
6/31 7/48 0.58
MMF, mycophenolate mofetil.
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A shortcoming of these studies4 17 is lack of protocol
biopsies. Optimal MMF dosing in patients maintained
on contemporary low-dose CNI is still undetermined.
However, some results of early MMF registration trials
suggest that higher MMF exposure might be beneﬁcial;
it must be kept in mind that there was no antibody
induction in these studies and that CNI was standard
dose cyclosporine. Thus, in the Tri-continental study, the
group treated with 3 g MMF compared with 2 g of MMF
showed lower incidence of biopsy proven acute rejection
episodes (15.9% vs 19.7%) within a 6 month period
selected for the primary efﬁcacy analysis. Similarly,
serum creatinine level at 1 year was 1.42±0.07 mg/dL in
the MMF 3 g group vs 1.64±0.07 mg/dL in the MMF 2 g
group.12 In the European MMF study the same trends
regarding higher MMF dose were observed.11 As men-
tioned before, in these studies there was no antibody
induction that could have allowed lower dose of cyclo-
sporin with higher dose of MMF and there were no
protocol biopsies. In a recent MYSS trial, there was no
difference in acute rejection rate and renal function
between MMF and azathioprine in a cyclosporine-based
protocol.18 However, in that study only one MMF dose
was compared to azathioprine21 and again there were no
protocol biopsies.
Unfortunately, adequate prospective MMF dose com-
parison studies in tacrolimus-based protocols with anti-
body induction are missing. In the Symphony study it
was reported that patients on tacrolimus-MMF-
prednisolone maintenance immunosuppression after
kidney transplantation had better kidney function and
graft survival with a lower number of acute rejection epi-
sodes. Patients in that group had highest MMF expos-
ure.22 Protocols with even higher MMF exposure might
allow additional CNI sparing, decreasing the side effects
of CNI (hypertension, diabetes, hyperlipidaemia,
neurotoxicity).1
Clinical relevance of IF/TA without other concomitant
pathology (ie, recurrent disease and chronic antibody-
mediated rejection) for prediction of graft deterioration
and loss is controversial. In the study by El-Zoghby et al
there was an attempt to identify speciﬁc causes of late
kidney allograft failure. The authors found that trans-
plant glomerulopathy was responsible for 37% loss of
functioning grafts, while graft loss due to IF/TA was
present in 31% of cases (with higher frequency in
deceased-donor transplants).23 At ﬁrst glance, these
results seem at odds with ours, where there were no
signs of chronic antibody-mediated rejection. An explan-
ation for this discrepancy in the results of the two
studies is not completely clear, but the former study
included a high number of living transplants (72.5%)
with glomerulonephritis as primary disease and with
follow-up of up to 10 years. Transplant glomerulopathy is
more frequently seen late post-transplant, generally with
low incidence. Nevertheless, ours and El-Zoghby study
demonstrated that IF/TA even in absence of other path-
ology is associated with adverse graft outcome. Another
important study, the DeKaf study, tried to use various
histopathological clusters to differentiate subgroups
within diagnosis of IF/TA. They found that the cluster
with more severe ﬁbrosis plus inﬂammation and arterial
lesions had the worst prognosis.24 Although incidence of
acute rejection in our study did not vary with MMF
exposure, increased MMF exposure might suppress mild
graft inﬂammation, below the threshold for diagnosing
acute rejection. This is the subject of our ongoing inves-
tigation and will be reported separately. An interesting
ﬁnding of the present study was that early steroid with-
drawal was not associated with worse IF/TA. At ﬁrst
glance this is at odds with the Astellas trial.21 However,
according to our protocol, patients with DGF were not
included in early steroid withdrawal and the Astellas trial
(which did not have protocol biopsies), reported
increased IF/TA in an early steroid withdrawal group
based on indication biopsies performed early post-
transplant, and were thus more likely reﬂecting donor-
derived histology changes, rather than the effect of
steroid withdrawal.25
In our study there was only borderline signiﬁcance of
positive association of 1-year eCrcl with MMF in univari-
ate analysis. This result is not very surprising since
decreased renal function is not a very sensitive marker
of incipient IF/TA.
Mechanisms by which an average higher exposure to
MMF was associated with slower progression of IF/TA
may be immune and non-immune. Owing to the fact
that there was no difference in incidence of acute rejec-
tion with respect to increased MMF exposure in our
study, we believe that there may be a signiﬁcant contri-
bution of non-immune mechanisms in retardation of
IF/TA in patients with higher MMF. In line with this, in
many experimental models it has been shown that MMF
has antiproliferative and antiﬁbrotic effects.13 26 27 In
the study of Jiang et al using rat renal ischaemia reperfu-
sion injury, a time-dependent and dose-dependent cor-
relation of higher MMF dose with better renal function
and lower interstitial ﬁbrosis was demonstrated.
Suggested potential mechanism was a lower expression
of transforming growth factor-β1 and monocyte chemo-
tactic protein-1 (MCP-1) with lower macrophage inﬁltra-
tion.27 In recent clinical trials MMF was shown as a safe
drug that could be a good candidate for treatment of
interstitial lung disease in systemic sclerosis.28 An experi-
mental model of encapsulated peritoneal sclerosis in
rats proved the beneﬁcial effect of MMF as an inhibitor
of neovascularisation.29 Also, MMF monotherapy was
associated with a positive effect on hepatic ﬁbrosis pro-
gression in hepatitis C virus liver transplant recipients.30
Our study has several shortcomings, such as its retro-
spective aspect and relatively short study period.
Although the study period was limited to 12 months
post-transplantation, a clear correlation of slower pro-
gression of IF/TA with a higher average MMF dose
underlines the potential beneﬁt of these ﬁndings. As
mentioned before, in the current study we did not
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analyse inﬂammation outside Banff acute rejection
threshold in kidney biopsies with respect to MMF dose.
As inﬂammation in areas of IF/TA is an important pre-
dictor of renal function and graft loss, it is the subject of
an ongoing work.
In summary, higher MMF dose after kidney transplant-
ation might slower progression of IF/TA, which can lead
to better long-term survival of transplanted kidney. Our
Our study serves as a platform for a prospective, rando-
mised, long-term trial with different MMF doses we are
currently conducting (trial registration number:
NCT018600183) to evaluate the beneﬁts of higher MMF
doses in renal transplant recipients.
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